Verus Pharmaceuticals

VERU INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Veru Inc. - VERU

Retrieved on: 
Monday, October 16, 2023
Class Action Lawsuit, Professional Services, Legal, COVID-19, Food, KSF, EUA, COVID, Emergency Use Authorization, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry, Verus Pharmaceuticals

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Veru Inc. (NasdaqCM: VERU).

Key Points: 
  • Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Veru Inc. (NasdaqCM: VERU).
  • Then, on March 2, 2023, the Company announced that the FDA formally declined its EUA request.
  • KSF’s investigation is focusing on whether Veru’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms.

Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants

Retrieved on: 
Wednesday, June 21, 2023
Partnership, University, College, Therapy, University of Tennessee Health Science Center, U.S. Department of Defense Strategy for Operating in Cyberspace, Pharmacy, The College of Medicine, SARS-CoV-2, UTHSC, United States Department of Defense, Cancer, National Cancer Institute, Research, Government, University of Florida College of Pharmacy, NCI, Distinguishing, Breast cancer, Pharmaceutical industry, Pathology, Verus Pharmaceuticals

MIAMI, FL, June 21, 2023 (GLOBE NEWSWIRE) -- The University of Tennessee Health Science Center (UTHSC), oncology drug discovery research partner to Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, has secured two additional grants to develop oncology therapeutics for indications of high unmet need. UTHSC was awarded $924,000 from the U.S. Department of Defense (DoD) and $3,074,470 from the National Cancer Institute’s Research Project Grant (NCI R01). These two new grants awarded to UTHSC bring the university’s aggregate oncology funding related to this project to over $10 million.

Key Points: 
  • UTHSC was awarded $924,000 from the U.S. Department of Defense (DoD) and $3,074,470 from the National Cancer Institute’s Research Project Grant (NCI R01).
  • These two new grants awarded to UTHSC bring the university’s aggregate oncology funding related to this project to over $10 million.
  • Validation of this research approach is reflected in peer-reviewed support from the U.S. government in the form of two awarded grants.
  • We are committed to collaborating with our clinical partner, Veru, who may ultimately pursue for late-stage clinical drug development.”

Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors

Retrieved on: 
Wednesday, May 31, 2023
Oncology, IPO, Partnership, Drug development, University, Therapy, Senior, Georgia Tech, Ear, Harvard University, AMD, Business, University of Pennsylvania, MBA, Nanomedicine, Inflammation, Cell, Messenger, Science, Regenerative medicine, MS, Wharton School of the University of Pennsylvania, Novartis, Patient, Verus Pharmaceuticals, Triple accreditation, Widener University Commonwealth Law School, Harvard Business School, ALS, Corporate development, Pharmaceutical industry, Ashvattha

“We are pleased to welcome Paul and Mahesh to Ashvattha,” said Jeff Cleland, Ph.D., CEO, co-founder, and Chairman of Ashvattha Therapeutics.

Key Points: 
  • “We are pleased to welcome Paul and Mahesh to Ashvattha,” said Jeff Cleland, Ph.D., CEO, co-founder, and Chairman of Ashvattha Therapeutics.
  • Prior to joining Ashvattha, Paul served as Chief Financial and Business Officer at Otonomy, a company that specialized in developing therapeutics for diseases and disorders of the ear.
  • Paul received his bachelor’s degree in biomechanical engineering from Harvard University and an MBA from the Harvard Business School.
  • Mahesh holds an MBA from the Wharton School, University of Pennsylvania, and an MS from Georgia Institute of Technology.

Veru to Present at the Jefferies Healthcare Conference

Retrieved on: 
Wednesday, May 24, 2023
Conference, Breast cancer, SARS-CoV-2, Pharmaceutical industry, Broadcasting, Verus Pharmaceuticals

MIAMI, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 11 a.m.

Key Points: 
  • MIAMI, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 11 a.m.
  • ET.
  • A live webcast will be accessible through the Investors section of the Company’s website at www.verupharma.com .
  • Following the event, an archived webcast will be available on the Veru website.

Lifshitz Law PLLC Announces Investigations of Generac Holdings Inc. (NYSE: GNRC), Veru Inc. (NASDAQ: VERU), The Gap, Inc. (NYSE: GPS), and NeoGenomics, Inc. (NASDAQ: NEO)

Retrieved on: 
Friday, March 17, 2023
EUA, Old Navy, NeoGenomics, Generac, Telephone, Marie Cassidy, Cancer, Emergency Use Authorization, Advertising, FDA, Hewlett, Safety, Mail, Pharmaceutical industry, Verus Pharmaceuticals

If you are a Generac investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are a Generac investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • If you are a Veru investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.
  • Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference

Retrieved on: 
Tuesday, March 7, 2023
Infection, Conference, COVID-19, Pharmaceutical industry, Verus Pharmaceuticals

MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 12 pm ET.

Key Points: 
  • MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 12 pm ET.
  • In this presentation, Veru's CEO plans to share the Company's current corporate strategy to focus on the clinical development of the drug candidates that have highly differentiated indications in both infectious disease and oncology with the near-term potential for Phase 3 clinical trial data in 2024.
  • A live webcast will be accessible through the Investors section of the Company’s website at www.verupharma.com .
  • Following the event, an archived webcast will be available on the Veru website.

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Veru Inc. (VERU) Investors of Class Action and to Actively Participate

Retrieved on: 
Monday, February 6, 2023
Class Action Lawsuit, Professional Services, Legal, FDA, Court, Complaint, NDA, Person, EUA, Verus Pharmaceuticals

Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/veru .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/veru .
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Veru Inc. (VERU)

Retrieved on: 
Friday, February 3, 2023
Class Action Lawsuit, Professional Services, Legal, FDA, Court, Law, Suite, Verus Pharmaceuticals, COVID-19, News, EUA, Cryptocurrency, Pharmaceutical industry

The Law Offices of Frank R. Cruz reminds investors of the upcoming February 6, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU ) common stock between May 11, 2022 and November 9, 2022, inclusive (the “Class Period”).

Key Points: 
  • The Law Offices of Frank R. Cruz reminds investors of the upcoming February 6, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU ) common stock between May 11, 2022 and November 9, 2022, inclusive (the “Class Period”).
  • If you purchased or otherwise acquired Veru common stock during the Class Period, you may move the Court no later than February 6, 2023 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

VERU 3-DAY DEADLINE ALERT: Hagens Berman Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm’s Attorneys Before Feb. 6th Deadline in Securities Class Action

Retrieved on: 
Friday, February 3, 2023
Person, COVID 19, News, COVID, Patient, SAN, FDA, EUA, Steve Berman (lawyer), Pharmaceutical industry, Verus Pharmaceuticals

SAN FRANCISCO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now .
  • VERU’s filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.
  • Investors learned the truth on Nov. 9, 2022, when Veru announced that the FDA advisory committee (“AdCom”) voted against approving sabizabulin under the agency’s EUA pathway.
  • If you invested in Veru and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

VERU INC. (NASDAQ: VERU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Veru Inc. (NASDAQ: VERU)

Retrieved on: 
Tuesday, January 31, 2023
Breast, Steiner, Prostate cancer, Safety, Fast Track, Trial of the century, COVID-19, The Legal 500, Fast track (FDA), Advertising, Court, Health minister, NDA, Labour government, Patient, FDA, District court, EUA, Investment, Mortality, Aerospace, Infection, Death, Prostate Cancer Foundation, News, Tobacco, Security (finance), Pharmaceutical industry, Verus Pharmaceuticals

NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU) between May 11, 2022 and November 9, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of Florida and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of Florida and alleges violations of the Securities Exchange Act of 1934.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.